Long QT Syndrome Genetics: Major Genes and Subtypes

Long QT syndrome is overwhelmingly a genetic condition, driven by mutations in genes that encode or regulate ion channels in heart muscle cells. Three genes account for the vast majority of cases: KCNQ1, KCNH2, and SCN5A, each responsible for a different subtype with distinct triggers, risk profiles, and treatment responses. But the genetics of long QT syndrome go well beyond identifying a single culprit gene. The same mutation can leave one family member symptom-free for life while causing sudden cardiac arrest in another, and at least a quarter of clinically diagnosed patients carry no identifiable mutation at all.

The Three Major Genes and What They Do

The heart’s electrical cycle depends on a precise sequence of ions flowing in and out of cardiac cells. Potassium channels help the cell return to its resting state after each beat, and sodium channels help initiate the electrical impulse. Mutations that slow this process down lead to a prolonged QT interval on an electrocardiogram, which is the electrical signature of delayed recovery between heartbeats. That delay creates a window during which dangerous heart rhythms can start.

In genetic testing of large groups of long QT syndrome patients, KCNQ1 mutations are consistently the most common, followed by KCNH2 and then SCN5A. One large real-world cohort of over a thousand index cases found that among the roughly 27% who tested positive for a disease-causing variant, KCNQ1 accounted for about half of all positive results, with KCNH2 and SCN5A making up most of the remainder.¹ A separate study with stricter clinical selection achieved a diagnostic yield of 75% in index patients, and every causal variant landed in one of these same three genes.² The diagnostic yield varies widely depending on how rigorously patients are clinically diagnosed before testing, which explains the spread between these numbers.

How Each Subtype Works Differently

Long QT syndrome type 1 (LQT1), caused by KCNQ1 mutations, disrupts a slow potassium current that helps the heart cell repolarize. Lab studies of specific LQT1 mutations show that some produce abnormal currents while others eliminate the current entirely. Many of these mutations also exert a dominant negative effect, meaning the faulty protein actively interferes with the normal copies, worsening the problem beyond what you’d expect from losing just one working gene copy.³ This helps explain why LQT1 is often more clinically apparent than some other subtypes.

Long QT syndrome type 2 (LQT2) involves KCNH2, which encodes a different potassium channel. About 90% of LQT2-causing mutations are missense mutations that disrupt the cell’s ability to transport the channel protein to the membrane surface. The defective proteins get stuck inside the cell’s internal processing machinery and are eventually destroyed before they ever reach the membrane.⁴ Other mechanisms, including altered current behavior and changes in ion selectivity, can also be at play.⁵

Long QT syndrome type 3 (LQT3) works by a fundamentally different mechanism. Instead of losing a potassium current, LQT3 involves gain-of-function mutations in SCN5A, the gene encoding the main cardiac sodium channel. These mutations cause the sodium channel to stay open longer than it should, allowing extra sodium to flow into the cell and delaying repolarization.⁶ Specifically, a small fraction of the sodium current becomes persistent rather than switching off on schedule.⁷ This distinction has direct treatment implications: a sodium channel blocker called mexiletine has been shown to shorten the QT interval and reduce life-threatening arrhythmic events specifically in LQT3 patients.⁸

Genotype Shapes When Danger Strikes

One of the most practically important findings in long QT genetics is that the subtype strongly predicts what triggers a dangerous cardiac event. In a landmark study of 670 patients with known genotypes, those with LQT1 experienced the majority of their cardiac events during exercise, while only 3% occurred during rest or sleep. LQT2 and LQT3 patients showed nearly the opposite pattern, with events far more likely during rest, sleep, or emotional arousal.⁹ Arousal-related events occurred in 85% of LQT1 patients compared with just 33% of LQT3 patients.¹⁰

Swimming is a particularly telling example. It is a relatively specific trigger for LQT1: among patients who experienced arrhythmias triggered by swimming, 85% had LQT1.¹¹ These trigger patterns matter for day-to-day management. An LQT1 patient may need different lifestyle modifications and closer monitoring during physical activity than an LQT3 patient, whose risk is higher at rest.

When the Same Mutation Means Different Things

Long QT syndrome is textbook incomplete penetrance. People in the same family carrying the exact same mutation can have wildly different outcomes. Some live their entire lives without a single symptom or even a noticeably long QT interval on their ECG. Others in the same generation and of the same sex experience cardiac arrest as children. Penetrance across different families has been reported to range from 25% to 100%.¹² There is even significant overlap in QT duration between mutation carriers and their unaffected family members who do not carry the mutation, which makes diagnosis by ECG alone unreliable in some cases.

This variability is not unique to long QT syndrome, but it is especially striking here because the consequences of being on the severe end can be sudden death. Multiple factors are thought to modulate severity. The specific location and type of mutation within the gene matters, as does sex, age, hormonal status, and the overall background of common genetic variants a person carries. A polygenic risk score for QT interval length has been tested in long QT syndrome cohorts. It explained only about 2% of QT variability in those patients, but probands had a significantly higher polygenic score than population controls, and patients with particularly long QT intervals had higher scores than those with shorter ones.¹³ In other words, the hundreds of common genetic variants that slightly influence QT duration in the general population also nudge long QT syndrome patients toward more or less severe disease, though the effect is modest compared to the primary mutation.¹⁴

Recessive Inheritance and Jervell and Lange-Nielsen Syndrome

Most long QT syndrome follows autosomal dominant inheritance, meaning a mutation in just one copy of the gene is enough to cause disease. But there is a recessive form that tends to be more severe. Jervell and Lange-Nielsen syndrome combines long QT syndrome with profound congenital deafness. It occurs when a person inherits two faulty copies of KCNQ1 or, less commonly, the related gene KCNE1. The parents, who each carry one copy, typically have the milder dominant form of long QT syndrome (or are asymptomatic carriers), while the child with two copies has both the cardiac rhythm abnormality and hearing loss because the same potassium channel is needed in the inner ear.¹⁵

There is also an autosomal recessive form without deafness, sometimes called autosomal recessive Romano-Ward syndrome. In this case the person has two KCNQ1 mutations but retains enough inner ear function to hear normally.¹⁶ These recessive forms tend to carry a higher arrhythmia risk than the typical single-mutation dominant forms, likely because both copies of the gene are compromised.

Rare and Severe Genetic Forms

Beyond the big three genes, some of the rarest forms of long QT syndrome are also the most dangerous. Calmodulinopathies, caused by mutations in the CALM1, CALM2, or CALM3 genes, tend to produce extremely prolonged QT intervals and present very early in life. An international registry of 140 patients with calmodulin variants found that long QT syndrome was the most common presentation, affecting about half the cohort. Three-quarters of all patients were symptomatic, with half experiencing an arrhythmic event by age six. All 26 patients who died suddenly did so before age 16, at an average age of about five and a half years.¹⁷ The average QT interval in calmodulin-associated long QT syndrome patients runs around 594 milliseconds, dramatically longer than what is seen in the more common subtypes.¹⁸

Timothy syndrome, caused by mutations in CACNA1C (a calcium channel gene), is another exceedingly rare form. It pairs long QT syndrome with features that extend well beyond the heart, including webbing of the fingers and toes, facial differences, and joint contractures. Novel mutations in this gene continue to be discovered, broadening the known clinical spectrum.¹⁹ Despite the severity of these rare forms, a key point from the calmodulinopathy literature is that early diagnosis and treatment can make a meaningful difference, and the condition is more treatable than its raw mortality numbers might suggest.²⁰

Not All “Long QT Genes” Are Created Equal

Over the years, as many as 17 genes have been reported as causes of long QT syndrome. A rigorous international reappraisal using modern evidence standards found that nine of those genes had limited or disputed evidence for actually causing the condition. The genes with strong or definitive evidence were essentially the usual suspects: KCNQ1, KCNH2, SCN5A, and a handful of others including the calmodulin genes.²¹ This matters practically: if a patient’s genetic test returns a variant in one of the disputed genes, it may be misleading to treat that as a confirmed diagnosis. The field has moved toward being more conservative, recognizing that early enthusiasm for novel gene discoveries sometimes outpaced the evidence.

Meanwhile, up to a quarter of patients with a strong clinical diagnosis of long QT syndrome have no identifiable mutation in any of the known genes. These “genetically elusive” cases are not necessarily milder. Limited data suggest their prognosis mirrors that of patients with identified mutations, which means the absence of a genetic finding does not rule out significant risk.²²

Drug-Induced Long QT and Genetic Susceptibility

Not everyone who takes a QT-prolonging medication develops a dangerously long QT interval. Genetics play a role in determining who is vulnerable to drug-induced long QT syndrome. Certain variants in the same genes that cause the congenital form can predispose people to problems when they encounter the wrong medication. The best-studied example is the KCNE1-D85N variant, which roughly doubles the odds of developing drug-induced QT prolongation.²³ A systematic evidence review rated KCNE1-D85N as having definitive evidence for drug-induced long QT risk, and a related variant, KCNE2-T8A, was rated as having strong evidence.²⁴

Beyond single variants, a polygenic risk score approach has also shown promise. A composite score reflecting the combined influence of many common variants was associated with about a 44% increase in odds of drug-induced long QT syndrome per standard deviation of the score in one validation study.²⁵ This suggests that in the future, pharmacogenomic screening before prescribing certain medications could help flag patients at higher risk.

Molecular Autopsy and Sudden Death in the Young

When a young person dies suddenly and the autopsy reveals no structural heart problem, genetic testing of preserved tissue (molecular autopsy) can sometimes identify a long QT syndrome mutation as the likely cause. Estimates suggest that roughly 25 to 35% of unexplained sudden deaths in young people that show nothing on standard autopsy may stem from mutations in long QT or related arrhythmia genes.²⁶ For sudden infant death syndrome specifically, about 10% of cases may be attributable to long QT syndrome mutations.

A population-based molecular autopsy study from New Zealand found pathogenic or likely pathogenic long QT variants in about 10% of sudden unexplained deaths in people aged 1 to 40.²⁷ The practical value extends beyond explaining a death that has already occurred. Family screening of the victim’s relatives identified living individuals with long QT syndrome or related conditions who then received appropriate management. A separate prospective study reached a similar 15% yield from genetic testing of sudden death cases, noting that family investigation combined with genetic testing supported transitioning molecular autopsy into routine forensic practice.²⁸

Fetal Detection and Early Life

Long QT syndrome can sometimes be suspected even before birth. In utero, the condition may present as unexplained fetal bradycardia, heart block, or ventricular tachycardia detected on fetal echocardiography. Diagnosing it prenatally is challenging because the standard tools used after birth — particularly the ECG — are not available, and the fetal heart rate abnormalities it causes can overlap with many other conditions.²⁹ When long QT syndrome does present in fetal life or the neonatal period, it tends to be a severe form, often involving the calmodulin genes or biallelic mutations, and carries high risk for life-threatening arrhythmias. A family history of long QT syndrome or unexplained sudden death in a previous child raises the index of suspicion considerably.

Gene Therapy on the Horizon

Researchers are exploring whether the root cause of long QT syndrome could eventually be corrected at the genetic level. One approach, called suppression-replacement therapy, simultaneously silences both the normal and mutant copies of the KCNQ1 gene and then introduces a new, functional copy that is immune to the silencing mechanism. In patient-derived heart cells grown in the lab, this strategy shortened the abnormally prolonged electrical recovery time back to near-normal levels, and it worked across multiple different LQT1-causing mutations.³⁰ The mutation-independent design is attractive because it means a single therapeutic vector could potentially treat many different LQT1 mutations rather than requiring a custom approach for each one.

For calmodulinopathy, a CRISPR-based strategy has been tested in patient-derived stem cells. By selectively knocking out the mutant copy of the calmodulin gene while leaving the two healthy copies intact, researchers corrected the prolonged electrical activity in lab-grown heart cells.³¹ Patient-derived cell models have proven essential for this kind of work. Induced pluripotent stem cells made from long QT syndrome patients faithfully reproduce the disease’s electrical signature, including the prolonged action potential and heightened susceptibility to arrhythmias triggered by adrenaline-like compounds.³² These cell models serve as both a testing ground for new therapies and a way to study how specific mutations actually affect heart cell behavior.

All of this work remains preclinical. No gene therapy for long QT syndrome has reached human trials yet. But the progress in lab-grown heart cells is encouraging, and the genetic precision of these approaches aligns with the broader trend in cardiology toward treating the specific molecular defect rather than just managing symptoms.